“A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas” (NCT05005845)
“Cladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral or infusion disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)” (NCT03933202)
“CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)” (NCT03933215)
NRG Oncology Foundation – NRG-BN007
08/06/21 – 08/05/22
Horta E, Bongiorno C, Ezzeddine M, Neil EC. Neurotoxicity of antibodies in cancer therapy: A review. Clinical neurology and neurosurgery. 2020 188:105566. PMID: 31731087.